| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.23 | 5e-06 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.24 | 6e-06 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.21 | 0.0005 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | -0.19 | 0.0007 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0008 |